AMRI recorded a $6.0m (€4.6m) operating loss in the second quarter as restructuring charges and the lack of milestone payments offset contract service gains.
Charles River Laboratories (CRL) has abandoned plans to buy Wuxi Pharmatech after the $1.6bn (€1.2bn) takeover failed to gain sufficient shareholder support.
Significant biopharm consolidation has played a key role in reshaping the drug development sector. Viq Pervaaz, senior vice president at Aon Consulting, discusses the changes and how they will impact on contract research organizations (CRO).
Icon reported a dip in operating income in the second quarter but an upturn in new business, and the cash to pursue M&A, make it reasonably positive about the future.
Encorium has bought Progenitor International Research, furthering efforts to fix its financial woes by focusing on vaccines, oncology and growth in emerging markets.
Major Charles River Laboratories (CRL) shareholder Jana Partners says Wuxi PharmaTech deal would generate inadequate returns, citing “industry” concerns about integration.
CRL has said the WuXi buy could add up to $100m (€78m) in additional annual revenue and spoken of clients’ enthusiasm for the deal as its attempts to shore up investor support.
M&A can help revitalize firms but failure to properly integrate the companies can create an inefficient, demoralized business. In this article, Viq Pervaaz, senior vice president at Aon Consulting, takes a look at M&A processes, pitfalls and keys...
Bristol-Myers Squibb (B-MS) has inked deals with Icon and Parexel to support the large volume of clinical development work it expects to perform in coming years.
Patheon has posted a 12 per cent growth in operating profit in the second quarter and said there is “strong evidence” the business environment is improving.
US-based contract research organisation (CRO) Novella Clinical has acquired Prologue Research to enhance its offering of oncology clinical trial services.
India-based Surya Pharmaceuticals is planning to raise Rs 500 crore ($100m) to fund construction of an active pharmaceutical ingredient (API) production plant, according to local media reports.
Cardiac monitoring and ePRO specialist ERT has added respiratory diagnostics and device manufacturing services to its offering with the acquisition of CareFusion Research Services (CRS) for $81m (€61m).
Charles River Laboratories (CRL) is to acquire WuXi PharmaTech for $1.6bn (€1.2bn), creating a global CRO capable of offering fully integrated services from molecule creation to first-in-human testing.
US CRO Medpace has move into medical device trials with acquisition of Symbios Clinical in a bid to tap into what CEO August Troendle said was a growth area for the contract research sector.
IT giant Oracle will pay $685m (€507m) for eClinical solutions firm Phase Forward, significantly expanding its presence in the billion dollar contract clinical research sector.
IRL and Epichem have entered into a strategic alliance to provide the Australasian pharma market with services from drug discovery through to cGMP production.
The capabilities of the MDS Pharma Services' sites Ricerca is set to acquire "perfectly dovetail" with its existing capacity, according to a company vice president.
Consolidation in pharma, coupled to the trend for strategic partnerships, will lead to CRO mergers, with large companies getting bigger and small firms focusing on niche opportunities, according to a report.
Belgium-based Galapagos NV has acquired Argenta Discovery for €16.5m ($23.1m), creating a drug discovery service company with 390 employees and estimated revenues of €70m.
MDS believes its early stage business is likely to sell for less than previously expected because of the continued deterioration of market conditions and its declining customer base.
US CRO PPD has sold its biomarker discovery sciences unit to Caprion Proteomics, bucking the trend that has seen many of its sector rivals invest in this part of the contract research market.
Quotient Bioresearch has secured the supply of 14C labelled compounds for its customers ahead of its move to a new purpose built facility in Cardiff through an extension of its agreement with GE Healthcare (GEHC).
US clinical trial review groups Independent Review Consulting (IRC) and Ethical Review Committee (ERC) are to merge and operate under the name Ethical and Independent Review Services (E&I).
Rexam will close its pill and tablet bottle making facility in New Hampshire, US by the end of the year to further align global plastics operations according to new CEO Graham Chipchase
Patheon says a slowdown in “outsourcing decision making,” manufacturing problems in Puerto Rico and cost related to JLL’s takeover bid hurt it in fiscal 09.
Patheon and JLL are to end the legal actions between them by entering into a litigation settlement which establishes a board of directors and limits JLL acquiring additional restricted voting shares before April 27 2012.
The recent wave of M&A will lead to manufacturing over-capacity at pharma companies but only a small number of these sites will be sold to CMOs, in part because of the facilities’ suboptimal locations, according to a report.
Icon is looking to expand its bioanalytical capacity in Asia, notably in China, and bolster its genomics, proteomics and cell-based assay capabilities, according to a VP who discussed diversification of the business.
MDS’ Central Labs has been rebranded as Clearstone Central Laboratories following its acquisition by Czura Thornton, which is looking to expand the business and that of Chiltern, a CRO also owned by the investment company, into new geographies, according...
MDS Pharma Services’ Central Labs division is to be acquired by Czura Thornton, a private investment group that owns Chiltern, for approximately $8m (€5.4m) as part of the CRO’s repositioning.
We look ahead to CPhI 2009 which takes place in Madrid, Spain next week and will showcase the world’s leading ingredients, contract services, machinery and biotech companies.
The outsourcing “market is poised to return to healthier growth rates in 2010”, according to the president of MDS Pharma Services who also told Outsourcing-Pharma that CROs will play an increasingly important role in drug development.
With Lonza and JLL competing over Patheon Outsourcing-Pharma looks at what the CMO offers to a prospective buyer, analysing its global manufacturing capacity and backlog using interactive maps and graphs.
CRO Averion is planning to become a private company to reduce expenditure on auditor fees, which could realise savings of $805,000 (€561,000), and allow management to better focus on long-term goals.
Cloud Packaging Solutions has said the acquisition of Toll Packaging will boost its ability to meet the increased demand for shorter packing runs triggered by the current global economic crisis.
